Гепатобилиарная сцинтиграфия в предоперационной оценке функции планируемого остатка печени (обзор литературы и собственные примеры)
https://doi.org/10.21682/2311-1267-2020-7-1-62-69
Аннотация
Резекция печени остается важнейшим этапом комбинированного лечения пациентов с опухолью печени, но она таит в себе риск развития пострезекционной печеночной недостаточности (ППН). Риск развития ППН зависит от качества (функции) и количества (объема) планируемого остатка печени. Поэтому всем пациентам, которым планируется обширная резекция печени, необходимо выполнять предоперационную оценку функции планируемого остатка печени. Гепатобилиарная сцинтиграфия с 99mTc-mebrofenin все чаще используется для количественной оценки функции планируемого остатка печени перед обширными резекциями печени.
Об авторах
Ю. Н. Ликарь
ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России
Россия
Россия
Юрий Николаевич Ликарь, д.м.н., заведующий отделением позитронно-эмиссионной томографии и радионуклидной диагностики
117997, Москва, ул. Саморы Машела, 1
Д. Г. Ахаладзе
ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России
Россия
Россия
к.м.н., руководитель группы торакоабдоминальной хирургии
117997, Москва, ул. Саморы Машела, 1
А. Г. Румянцев
ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России
Россия
Россия
академик РАН, д.м.н., профессор, президент РОО НОДГО и НМИЦ ДГОИ им. Дмитрия Рогачева, главный внештатный детский специалист онколог-гематолог Минздрава России
117997, Москва, ул. Саморы Машела, 1
Список литературы
1. Petrick J.L., Braunlin M., Laversanne M., Valery P.C., Bray F., McGlynn K.A. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer 2016;139(7):1534–45. doi.org/10.1002/ijc.30211.
2. Valery P.C., Laversanne M., Clark P.J., Petrick J.L., McGlynn K.A., Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology 2018;67(2):600–11. doi:10.1002/hep.29498.
3. Howlader N., Noone A.M., Krapcho M., Miller D., Bishop K., Altekruse S.F., Kosary C.L., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., Chen H.S., Feuer E.J., Cronin K.A. (eds). SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. https://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
4. van den Broek M.A., Olde Damink S.W., Dejong C.H., Lang H., Malago M., Jalan R., Saner F.H. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 2008;28(6):767–80. doi: 10.1111/j.1478-3231.2008.01777.x.
5. Rahbari N.N., Garden O.J., Padbury R., Brooke-Smith M., Crawford M., Adam R., Koch M., Makuuchi M., Dematteo R.P., Christophi C., Banting S., Usatoff V., Nagino M., Maddern G., Hugh T.J., Vauthey J.N., Greig P., Rees M., Yokoyama Y., Fan S.T., Nimura Y., Figueras J., Capussotti L., Buchler M.W., Weitz J. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011;149(5):713–24. doi: 10.1016/j.surg.2010.10.001.
6. Kauffmann R., Fong Y. Post-hepatectomy liver failure. Hepatobiliary Surg Nutr 2014;3(5):238–46. doi: 10.3978/j.issn.2304-3881.2014.09.01.
7. Abdalla E.K., Vauthey J.N. Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful? Dig Surg 2008;25(6):421–9. doi: 10.1159/000184733.
8. Cucchetti A., Cescon M., Ercolani G., Di Gioia P., Peri E., Pinna A.D. Safety of hepatic resection in overweight and obese patients with cirrhosis. Br J Surg 2011;98(8):1147–54. doi.org/10.1002/bjs.7516.
9. Vetelainen R., van Vliet A., Gouma D.J., van Gulik T.M. Steatosis as a risk factor in liver surgery. Ann Surg 2007;245(1):20–30. doi: 10.1097/01.sla.0000225113.88433.cf.
10. Agrawal S., Belghiti J. Oncologic resection for malignant tumors of the liver. Ann Surg 2011;253(4):656–65. doi: 10.1097/SLA.0b013e3181fc08ca.
11. Jarnagin W.R., Gonen M., Fong Y., DeMatteo R.P., Ben-Porat L., Little S., Corvera C., Weber S., Blumgart L.H. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236(4):397–406; discussion 406–397. doi: 10.1097/01.SLA.0000029003.66466.B3.
12. Kamath P.S., Kim W.R., Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology 2007;45(3):797–805. doi: 10.1002/hep.21563.
13. Kokudo N., Vera D.R., Makuuchi M. Clinical application of TcGSA. Nucl Med Biol 2003;30(8):845–9. doi: 10.1016/s0969-8051(03)00113-6.
14. Lau H., Man K., Fan S.T., Yu W.C., Lo C.M., Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997;84(9):1255–9. doi.org/10.1046/j.1365-2168.1997.02770.x.
15. Schneider P.D. Preoperative assessment of liver function. Surg Clin North Am 2004;84(2):355–73. doi: 10.1016/S0039-6109(03)00224-X.
16. Schroeder R.A., Marroquin C.E., Bute B.P., Khuri S., Henderson W.G., Kuo P.C. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006;243(3):373–9. doi: 10.1097/01.sla.0000201483.95911.08.
17. Clavien P.A., Emond J., Vauthey J.N., Belghiti J., Chari R.S., Strasberg S.M. Protection of the liver during hepatic surgery. J Gastrointest Surg 2004;8(3):313–27. doi: 10.1016/j.gassur.2003.12.006.
18. Shoup M., Gonen M., D’Angelica M., Jarnagin W.R., DeMatteo R.P., Schwartz L.H., Tuorto S., Blumgart L.H., Fong Y. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003;7(3):325–30. doi: 10.1016/s1091-255x(02)00370-0.
19. Vauthey J.N., Chaoui A., Do K.A., Billimoria M.M., Fenstermacher M.J., Charnsangavei C., Hicks M., Alsfasser G., Lauwers G., Hawkins I.F., Caridi J. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000;127(5):512–9. doi: 10.1067/msy.2000.105294.
20. Cieslak K.P., Bennink R.J., de Graaf W., van Lienden K.P., Besselink M.G., Busch O.R., Gouma D.J., van Gulik T.M. Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection. HPB (Oxford) 2016;18(9):773–80. doi: 10.1016/j.hpb.2016.06.006.
21. Olthof P.B., Coelen R.J.S., Bennink R.J., Heger M., Lam M.F., Besselink V.G., Busch O.R., van Lienden K.P., van Gulik T.M. (99m)Tc-mebrofenin hepatobiliary scintigraphy predicts liver failure following major liver resection for perihilar cholangiocarcinoma. HPB (Oxford) 2017;19(10):850–8. doi: 10.1016/j.hpb.2017.05.007.
22. Olthof P.B., Tomassini F., Huespe P.E., Truant S., Pruvot F.R., Troisi R.I., Castro C., Schadde E., Axelsson R., Sparellid E., Bennink R.J., Adam R., van Gulik T.M., de Santibanes E. Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: Liver volume overestimates liver function. Surgery 2017;162(4):775–83. doi: 10.1016/j.surg.2017.05.022.
23. Clavien P.A., Petrowsky H., DeOliveira M.L., Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356(15):1545–59. doi: 10.1056/NEJMra065156.
24. Akaki S., Mitsumori A., Kanazawa S., Togami I., Takeda Y., Joja I., Hiraki Y. Technetium-99 m-DTPA-galactosyl human serum albumin liver scintigraphy evaluation of regional CT/MRI attenuation/signal intensity differences. J Nucl Med 1998;39(3):529–32. PMID: 9529304.
25. Marshall J.S., Green A.M., Pensky J., Williams S., Zinn A., Carlson D.M. Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage. J Clin Invest 1974;54(3):555–62. doi: 10.1172/JCI107792.
26. Nanashima A., Yamaguchi H., Shibasaki S., Morino S., Ide N., Takeshita H., Sawai T., Nakagoe T., Nagayasu T., Ogawa Y. Relationship between indocyanine green test and technetium- 99 m galactosyl serum albumin scintigraphy in patients scheduled for hepatectomy: Clinical evaluation and patient outcome. Hepatol Res 2004;28(4):184–90. doi: 10.1016/j.hepres.2003.11.010.
27. Iimuro Y. ICG Clearance Test and 99mTc-GSA SPECT/CT Fusion Images. Visc Med 2017;33(6):449–54. doi: 10.1159/000479046.
28. Sumiyoshi T., Okabayashi T., Negoro Y., Hata Y., Noda Y., Sui K., Iwata J., Mutsumoto M. (99m)Tc-GSA SPECT/CT fusion imaging for hepatectomy candidates with extremely deteriorated ICG value. Jpn J Radiol 2018;36(9):537–43. doi: 10.1007/s11604-018-0753-0.
29. Fujioka H., Kawashita Y., Kamohara Y., Yamashita A., Mizoe A., Yamaguchi J., Azuma A., Furui J., Kanematsu T. Utility of technetium-99m-labeled-galactosyl human serum albumin scintigraphy for estimating the hepatic functional reserve. J Clin Gastroenterol 1999;28(4):329–33. doi: 10.1097/00004836-199906000-00009.
30. Mimura T., Hamazaki K., Sakai H., Tanaka N., Mimura H. Evaluation of hepatic functional reserve in rats with obstructive jaundice by asyaloglycoprotein receptor. Hepatogastroenterology 2001;48(39):777–82. PMID: 11462923.
31. Beppu T., Hayashi H., Okabe H., Masuda T., Mima K., Otao R., Chikamoto A., Doi K., Ishiko T., Takamori H., Yoshida M., Shiraishi S., Yamashita Y., Baba H. Liver functional volumetry for portal vein embolization using a newly developed 99mTc-galactosyl human serum albumin scintigraphy SPECT-computed tomography fusion system. J Gastroenterol 2011;46(7):938–43. doi: 10.1007/s00535-011-0406-x.
32. Hwang E.H., Taki J., Shuke N., Nakajima K., Kinuya S., Konishi S., Michigishi T., Aburano T., Tonami N. Preoperative assessment of residual hepatic functional reserve using 99 mTc-DTPA-galactosyl-human serum albumin dynamic SPECT. J Nucl Med 1999;40(10):1644–51. PMID: 10520704.
33. Satoh K., Yamamoto Y., Nishiyama Y., Wakabayashi H., Ohkawa M. 99 mTc-GSA liver dynamic SPECT for the preoperative assessment of hepatectomy. Ann Nucl Med 2003;17(1):61–7. doi: 10.1007/bf02988261.
34. Hasegawa D., Onishi H. Evaluation of Accuracy for Quantitative Predictor of Hepatic Functional Reserve Using Planar and SPECT Images in the (99m)Tc-GSA Scintigraphy. Nihon Hoshasen Gijutsu Gakkai Zasshi 2017;73(10):1055–60. doi: 10.6009/jjrt.2017_JSRT_73.10.1055.
35. Loberg M.D., Cooper M., Harvey E., Callery P., Faith W. Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid. J Nucl Med 1976;17(7):633–8. PMID: 1271111.
36. Ghibellini G., Leslie E.M., Pollack G.M., Brouwer K.L. Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res 2008;25(8):1851–60. doi: 10.1007/s11095-008-9597-0.
37. Krishnamurthy G.T., Krishnamurthy S. Cholescintigraphic measurement of liver function: how is it different from other methods? Eur J Nucl Med Mol Imaging 2006;33(10):1103–6. doi: 10.1007/s00259-006-0182-7.
38. Leonard J.C., Hitch D.C., Manion C.V. The use of diethyl-IDA Tc 99 m clearance curves in the differentiation of biliary atresia from other forms of neonatal jaundice. Radiology 1982;142(3):773–6. doi: 10.1148/radiology.142.3.7063701.
39. Gambhir S.S., Hawkins R.A., Huang S.C., Hall T.R., Busuttil R.W., Phelps M.E. Tracer kinetic modeling approaches for the quantification of hepatic function with technetium-99 m DISIDA and scintigraphy. J Nucl Med 1989;30(9):1507–18. PMID: 2769404.
40. Ekman M., Fjalling M., Friman S., Carlson S., Volkmann R. Liver uptake function measured by IODIDA clearance rate in liver transplant patients and healthy volunteers. Nucl Med Commun 1996;17(3):235–42. doi: 10.1097/00006231-199603000-00011.
41. de Graaf W., van Lienden K.P., van Gulik T.M., Bennink R.J. (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy. J Nucl Med 2010;51(2):229–36. doi: 10.2967/jnumed.109.069724.
42. Erdogan D., Heijnen B.H., Bennink R.J., Kok M., Dinant S., Straatsburg I.H., Gouma D.J., van Gulik T.M. Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test. Liver Int 2004;24(2):117–23. doi: 10.1111/j.1478-3231.2004.00901.x.
43. Chapelle T., Op De Beeck B., Huyghe I., Francque S., Driessen A., Roeyen G., Ysebaert D., De Greef K. Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure? HPB (Oxford) 2016;18(6):494–503. doi: 10.1016/j.hpb.2015.08.002.
44. Geisel D., Ludemann L., Froling V., Malinowski M., Stockmann M., Baron A., Gebauer B., Seehofer D., Prasad V., Denecke T. Imaging-based evaluation of liver function: comparison of (9)(9)mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI. Eur Radiol 2015;25(5):1384–91. doi: 10.1007/s00330-014-3536-8.
45. Serenari M., Collaud C., Alvarez F.A., de Santibanes M., Giunta D., Pekoij J., Ardiles V., de Santibanes E. Interstage Assessment of Remnant Liver Function in ALPPS Using Hepatobiliary Scintigraphy: Prediction of Posthepatectomy Liver Failure and Introduction of the HIBA Index. Ann Surg 2018;267(6):1141–7. doi: 10.1097/SLA.0000000000002150.
46. Mosteller R.D. Simplified calculation of body-surface area. N Engl J Med 1987;317(17):1098. doi: 10.1056/NEJM198710223171717.
47. Rassam F., Olthof P.B., Richardson H., van Gulik T.M., Bennink R.J. Practical guidelines for the use of technetium-99m mebrofenin hepatobiliary scintigraphy in the quantitative assessment of liver function. Nucl Med Commun 2019;40(4):297–307. doi:10.1097/MNM.0000000000000973.
48. de Graaf W., van Lienden K.P., van den Esschert J.W., Bennink R.J., van Gulik T.M. Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg 2011;98(6):825–34. doi: 10.1002/bjs.7456.
Рецензия
Для цитирования:
Ликарь Ю.Н., Ахаладзе Д.Г., Румянцев А.Г. Гепатобилиарная сцинтиграфия в предоперационной оценке функции планируемого остатка печени (обзор литературы и собственные примеры). Российский журнал детской гематологии и онкологии (РЖДГиО). 2020;7(1):62-69. https://doi.org/10.21682/2311-1267-2020-7-1-62-69
For citation:
Likar Yu.N., Akhaladze D.G., Rumyantsev A.G. Hepatobiliary scintigraphy in the preoperative assessment of the future remnant liver function (literature review and own examples). Russian Journal of Pediatric Hematology and Oncology. 2020;7(1):62-69. (In Russ.) https://doi.org/10.21682/2311-1267-2020-7-1-62-69
Просмотров: 650
Послать статью по эл. почте 